Central Indiana is already home to the nation’s largest cluster of radiopharmaceutical companies and now local officials say the hub is hotter than ever.
BioCrossroads, the initiative to grow and promote Indiana’s life sciences sector, says the state has secured the designation of Radiopharmaceutical Capital of the World from the U.S. Patent and Trademark Office.
Radiopharmaceuticals are drugs that contain radioisotopes and are used to treat various medical conditions, including different types of cancer and hyperthyroidism. According to Purdue University, the nuclear medicine market is a $6 billion industry in the U.S.
Indianapolis-based SpectronRx opened its headquarters in 2019 and has grown from a staff of six to 175 in Indianapolis as of December 2024. The company also has a facility near the Grissom Air Reserve Base in Bunker Hill used to produce medical isotopes used in radiopharmaceuticals.
CEO John Zehner has more than 30 years of experience in the nuclear medicine industry and says the industry’s growth is surprising.
“If I was to try to predict this five years ago, no way. It wasn’t even on the radar. It’s been pretty amazing,” Zehner told Inside INdiana Business of Health reporter Kylie Veleta. “We have several companies that have put facilities here. There’s so many jobs being created in this sector, and I’m just happy to be part of it. We feel very fortunate to be part of the Indianapolis ecosystem here, and we look forward to it growing.”
Purdue is partnering with SpectronRx to build a dedicated radiopharmaceutical manufacturing training facility at the company’s headquarters. It’s part of what Purdue says is the country’s first graduate degree program focused directly on radiopharmaceutical manufacturing.
The facility will be complete with clean rooms and quality control equipment and students will also learn how to respond to a “spill” – which in the nuclear medicine world, is likely just one or two atoms.
“That’s probably one of the most interesting things that we can do is mockup that spill, then teach people how to react to that spill,” Zehner said. “It’s going to have a complete mockup of multiple different situations that you can have in radiopharmaceutical manufacturing or in nuclear medicine.”
Zehner says about 25% of the company’s current employees are Purdue alumni. The school’s new master’s in radiopharmaceutical manufacturing will be offered starting in the spring 2026 semester and will feature a hybrid format with most courses completed online and students required to complete an in-person capstone course.
“We’ve been able to find people, but definitely, training is always an issue. So if you can have an advanced degree in our field, which is rare, that really is a positive,” Zehner said. “SpectronRx is an enabler in the field, so we help people label their medication with radioactivity, or actually even produce the radio isotopes for that labeling. So this is really just another step where we were able to work with Purdue.”
Earlier this year, BioCrossroads announced that Indiana was the nation’s largest exporter of life sciences products in 2024. The industry generated $99 billion in economic activity, according to the organization’s report.
According to Purdue, Indiana is home to 15 nuclear medicine companies, including New Jersey-based drugmaker Bristol Myers Squibb.
Earlier this month, the company dedicated its only production facility in Indiana, a former north-side warehouse transformed with $160 million into a clean-room manufacturing site for radiopharmaceutical cancer therapies.
The treatments produced at Bristol Myers Squibb unit RayzeBio’s factory in Indianapolis are for clinical trials and are not yet FDA-approved. But the company is banking on the medications as more effective cancer treatments than traditional chemotherapy. Officials describe the treatments as precision medicine capable of delivering a fatal blow to cancer cells while sparing organs and healthy tissue.
Novartis, which opened its Indianapolis manufacturing facility just two years ago, is already expanding and adding an additional plant to the campus.
The state is also home to a growing number of innovators including AZIsotopes, Oranomed, Curium, and Telix Pharmaceuticals.
“Indiana’s designation as the Radiopharmaceutical Capital of the World is a testament to the strength of our life sciences ecosystem, the innovation of our researchers, and the collaborative spirit that drives us forward,” BioCrossroads CEO Vince Wong said in a news release. “We’ll leverage this fitting title to further elevate Indiana as a center of excellence in this exciting, dynamic area of medicine that is helping transform the standard of care to the benefit of patients throughout the world.”
IBJ health care and life sciences reporter Daniel Lee and IIB Managing Editor Alex Brown contributed to this story.
